[
  {
    "ts": null,
    "headline": "Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed",
    "summary": "Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed (RMD) with a $286 price target after Apnimed provided topline results as part of its Phase 3 trial for AD109, focused on the treatment of obstructive sleep apnea. Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% from baseline, the analyst tells investors in a research note. The firm believes AD109 appears to focus on patients who are unable or refuse to tolerate continuous positive air",
    "url": "https://finnhub.io/api/news?id=3fcb054e5e78705ec69b5d98412332d341c65db812bf6f64ba045690e4fc46c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747836608,
      "headline": "Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed",
      "id": 134628943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "Morgan Stanley analyst David Bailey keeps an Overweight rating on ResMed (RMD) with a $286 price target after Apnimed provided topline results as part of its Phase 3 trial for AD109, focused on the treatment of obstructive sleep apnea. Participants treated with AD109 recorded a mean Apnea-Hypopnea Index reduction of 55.6% from baseline, the analyst tells investors in a research note. The firm believes AD109 appears to focus on patients who are unable or refuse to tolerate continuous positive air",
      "url": "https://finnhub.io/api/news?id=3fcb054e5e78705ec69b5d98412332d341c65db812bf6f64ba045690e4fc46c9"
    }
  }
]